Reports
| Status | Drug name | NICE TAs | Comments |
|---|---|---|---|
 |
Levosimendan injection | Hospital use only |
|
 |
Lidocaine 5% patch | For patients who have been treated in line with NICE CG173 Neuropathic pain in adults: pharmacological management in non-specialist settings but are still experiencing neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia) |
|
|
Lidocaine hydrochloride | Hospital only |
|
|
Lignocaine 5% medicated plasters (30 plasters) | RICaD |
|
|
Linaclotide | For moderate to severe IBS-Constipation. For patients who have not responded adequately to or cannot tolerate all other suitable treatment options BUT BEFORE other agents with higher costs. |
|
|
Liothyronine tablets | ESCA in development |
|
 |
Liquid paraffin (VitA-POS®) | Second line |
|
|
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name) | The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. |
|
|
Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name) | THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary. |
|
|
Lisdexamfetamine | ESCAs and additional advice in relation to age of patient and CCG |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- Next page
- Last page
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
